NCT07090369View on ClinicalTrials.gov

Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

December 1, 2028

Study Completion Date

December 1, 2028

Conditions
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Interventions
DRUG

Olaparib (300 mg BID)

oral tablet

DRUG

Pembrolizumab

IV infusion

RADIATION

177Lu-PSMA-I&T

PSMA-I\&T is a small molecule ligand that binds to the extra-cellular domain of the prostatespecific membrane antigen. PSMA-I\&T is a small molecule ligand that binds to the extra-cellular domain of the prostatespecific membrane antigen

Trial Locations (1)

3000

Peter MacCallum Cancer Centre, Melbourne

All Listed Sponsors
lead

Peter MacCallum Cancer Centre, Australia

OTHER